Journal of neural transmission (Vienna, Austria : 1996)最新文献

{"title":"Lifestyle medicine for neuroprotection: evidence and implementation in Asian contexts.","authors":"Sumin Kim, Seok Jong Chung, Soyeon Yoon, Bastiaan R Bloem, Elbrich Postma, Ryul Kim, Shinsuke Fujioka, Yukiko Nagaishi, Onanong Phokaewvarangkul, Kye Won Park, Eng-King Tan, Surasa Khongprasert, Jinyoung Youn","doi":"10.1007/s00702-026-03294-x","DOIUrl":"https://doi.org/10.1007/s00702-026-03294-x","url":null,"abstract":"<p><p>In Parkinson's disease (PD), the limitations in disease-modifying therapies have broadened the concept of neuroprotection beyond targeting specific pathogenic pathways to include the strengthening of motor reserve and resilience through modifiable lifestyle factors. This review synthesizes current evidence on lifestyle medicine for PD, focusing on its potential contribution to neuroprotection, symptom control, and implementation in Asian contexts. We first discuss physical activity and exercise, including community-based and technology-assisted approaches, as interventions that improve motor and non-motor outcomes and may have long-term disease-modifying potential. We then review nutrition from prevention-oriented, genetic, and disease-stage-specific perspectives, including dietary patterns, caffeine and tea exposure, and nutritional vulnerability in established PD. Sleep health and stress management are considered as interconnected determinants of daily function, quality of life (QoL), and resilience. We further discuss integrated lifestyle medicine as a multidomain care model that combines core lifestyle pillars with personalized, sustainable, and culturally responsive implementation. Future directions may include rigorous validation, practical implementation models, and digitally enabled monitoring tailored to diverse Asian healthcare systems. Although definitive disease-modifying effects remain unproven, integrated lifestyle medicine may offer a practical foundation for translating accumulating lifestyle evidence into more rigorous and scalable neuroprotective strategies for PD.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.","authors":"Mario Hero, Eliša Papić, Nadja Grozdanić, Vladimira Vuletić","doi":"10.1007/s00702-026-03300-2","DOIUrl":"https://doi.org/10.1007/s00702-026-03300-2","url":null,"abstract":"<p><p>Patients with Parkinson's disease now live for decades after deep brain stimulation, and many develop recurrent symptoms while the stimulator still functions. A continuous infusion is sometimes added, but the circumstances justifying it are undefined, and the two modalities are still viewed as competing rather than complementary. This review examines the addition of the four infusion therapies after stimulation. A search of three databases identified fifteen reports, almost all small and retrospective. They report 118 patients and 119 infusion courses: 68 with intestinal levodopa gel, 23 with apomorphine, 28 with foslevodopa/foscarbidopa, and none with entacapone. Off time fell in every study that measured it, though fewer than half did. The on-state motor examination improved significantly only in the largest series to test it. In a post hoc trial subgroup, off time improved similarly with and without previous stimulation, while activities of daily living and speech improved significantly less in those with prior stimulation. Severe adverse events were more frequent after prior stimulation. The combination is uncommon: 1% to 2% of patients in larger cohorts, under 0.1% in a national apomorphine cohort. Stimulation parameters are reported or unchanged in only 10 of the 118 patients, and primary failure cannot be separated from secondary failure in 29. We propose a structured assessment separating correctable device problems, recurrent dopaminergic symptoms, stimulation-induced effects and levodopa-resistant progression. Infusion therapy may help recurrent levodopa-responsive complications after stimulation has been re-evaluated and optimized. Its use in late axial or cognitive decline is untested rather than disproven.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GNAL-associated dystonia: clinical spectrum, genetic features, and genotype-phenotype correlations.","authors":"Rohan R Mahale, Pramod Khanda, H Shravan, Subhajit Roy, Hansashree Padmanabha, Pooja Mailankody","doi":"10.1007/s00702-026-03298-7","DOIUrl":"https://doi.org/10.1007/s00702-026-03298-7","url":null,"abstract":"<p><p>Despite increasing recognition of GNAL-associated dystonia as a genetic cause of adult-onset isolated cervical dystonia, the full phenotypic spectrum, longitudinal pattern of disease progression, and genotype-phenotype relationships remain incompletely defined. We retrospectively reviewed our case of genetically confirmed patient with GNAL-associated dystonia and reviewed genetically confirmed cases published up to June 2026. Demographic, clinical, treatment, neuroimaging, and genetic data were extracted. Genotype-phenotype comparisons were performed between patients with missense and loss-of-function (LoF) variants. Our review showed seventy-six patients, with a median age at onset of 35 years (IQR, 22-44) and female predominance (57.9%). Dystonia was predominantly focal at onset, with cervical dystonia being most common; and 54% patients with focal onset progressed to segmental or generalized dystonia, with a median time to generalization of 6 years. Most patients had isolated dystonia. Among 46 detected genetic variants, missense variants predominated and nearly all were heterozygous. Twelve patients underwent globus pallidus interna deep brain stimulation (GPi-DBS), with greatest benefit for cervical dystonia. The LoF variants were associated with a shorter time to generalization than missense variants (2 vs. 10 years, p=0.021). This association was not confirmed in a censoring-based survival analysis (log-rank p=0.904) and should be regarded as hypothesis-generating. GNAL-associated dystonia presents as adult-onset isolated dystonia with focal onset, with substantial longitudinal progression to segmental or generalized dystonia (54%). GPi-DBS appears beneficial, particularly for cervical dystonia. The genetic spectrum is highly heterogeneous, with predominantly heterozygous missense distributed across the α-helical and Ras-like GTPase domains. The observed association between LoF variants and more rapid generalization warrants validation in larger longitudinal cohorts.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight changes and physical activity in Parkinson's disease: converging markers of energy balance, disease progression, and lifestyle-based care.","authors":"Daniele Urso, Giancarlo Logroscino","doi":"10.1007/s00702-026-03297-8","DOIUrl":"https://doi.org/10.1007/s00702-026-03297-8","url":null,"abstract":"<p><p>Weight changes are common but often overlooked in Parkinson's disease (PD), occurring across prodromal, early, and advanced disease stages. Weight loss may reflect increased energy expenditure, dysautonomia, dysphagia, gastrointestinal dysfunction, altered appetite, and involvement of central pathways regulating hunger, satiety, and reward. Conversely, weight gain may occur in relation to dopaminergic treatment, impulse-control or binge-eating behaviours, reduced mobility, and post-surgical changes. Emerging longitudinal data suggest that weight variability is not merely a nutritional issue, but may identify distinct clinical trajectories, including faster cognitive and functional decline in patients with weight loss and different motor/non-motor patterns in those with weight gain. In parallel, physical activity and structured exercise are increasingly recognized as central components of PD care, with evidence supporting symptomatic benefits, possible disease-modifying effects, and even a protective association against incident PD. This review examines the intersection between weight changes and physical activity in PD, proposing that both reflect a broader disruption of energy balance, motor reserve, metabolic regulation, and lifestyle-related resilience. We discuss clinical mechanisms, biomarkers, prognostic implications, and practical approaches to integrate weight monitoring, nutritional assessment, and individualized physical activity prescriptions into routine PD care.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.","authors":"Kurt A Jellinger","doi":"10.1007/s00702-026-03293-y","DOIUrl":"https://doi.org/10.1007/s00702-026-03293-y","url":null,"abstract":"<p><p>Schizophrenia is a complex, heterogeneous, and disabling psychiatric disorder that disrupts cognitive, perceptual, and emotional functioning. In over 70% of patients, it is associated with multiple psychiatric and somatic comorbidities that, together with lifestyle and substance abuse, contribute to lower quality of life and reduced life expectancy. Other major psychiatric comorbidities, such as anxiety, depression, and bipolar disorder, often show considerable overlap with schizophrenic symptoms and are difficult to differentiate. The substrate of dementia in older schizophrenics and co-existing Alzheimer disease is a matter of discussion. Other common comorbidities like obsessive-compulsive and personality disorders predominate, while prenatal risk factors such as dysmorphologies, hypoxia, and infections may occur premorbidly or at illness onset. Among somatic comorbidities, cardiovascular and cerebrovascular diseases, metabolic syndrome, and diabetes are most frequent and show some genetic overlap with schizophrenia. Clinical and research interests in the co-occurring issues of schizophrenia are caused by the presence of multiple coexisting psychopathologies as well as comorbid medical conditions that may increase mortality. Current evidence suggests involvement of multiple neurotransmitter systems (dopaminergic, glutamatergic, and GABAergic), prefrontal cortical involvement, and corticostriate-thalamo-cortical circuit dysfunctions in the pathogenesis of both schizophrenia and many key psychiatric comorbidities, while the evidence implicating biological pathways affecting both body and brain is increasing for most somatic comorbidities. Although environmental bias increases throughout the disease course, the pathogenic factors for the majority of concurrent pathologies and their clinical implications warrant further attention.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access, stigma and community engagement: implementation strategies for rural and underserved populations.","authors":"Priya Jagota, Eliza Zhunusova, Rajeev Ojha, Maria Barretto, Appasone Phoumindr, Yin Minn Aye, Frandy Susatia","doi":"10.1007/s00702-026-03292-z","DOIUrl":"https://doi.org/10.1007/s00702-026-03292-z","url":null,"abstract":"<p><p>Parkinson's disease remains one of the fastest growing neurodegenerative disorder. Optimal care for the patients may include proper medication dispensation and adjustment, physiotherapy, speech and swallowing therapy, and in some cases advanced device-aided therapy. These may incur a high cost and rendered unaffordable, especially in lower socioeconomic countries where government subsidies maybe limited. Moreover, gaining access to care may be difficult and expensive, especially among those in rural areas. Additionally, cultural contexts may delay care-seeking, especially in Asia where the concept of \"face\" plays a prominent role in society. Here, we briefly review the current status of access to care in Asia, stigma in the context of Asian patients, and how community engagement can help reduce the barriers to care of people with Parkinson's. We provide various ways to engage the community, their barriers and how they could be overcome, and two real-life examples of community engagement done in India and Thailand to reduce the gap in care, stigma and increase public awareness of Parkinson's.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On-demand therapies-emergency medication or daily routine?","authors":"David Weise, Florin Gandor","doi":"10.1007/s00702-026-03288-9","DOIUrl":"https://doi.org/10.1007/s00702-026-03288-9","url":null,"abstract":"<p><p>Fluctuations represent a major therapeutic challenge in Parkinson's disease (PD) and become increasingly prevalent with disease progression. While oral and device-aided therapies (DAT) improve symptom control, patients continue to experience disabling OFF episodes, in particular early morning OFFs, delayed ON, and no-ON phenomena. Increasing evidence suggests that both motor and non-motor fluctuations are more common than previously recognized and contribute substantially to impaired quality of life. Fluctuations affect up to 50% of patients within five years of disease onset to eventually affect almost all patients with longer duration. Beside altered central pharmacodynamics, peripheral mechanisms such as dysphagia, gastroparesis, altered intestinal absorption, and microbiome-mediated levodopa degradation, contribute to fluctuations. Although oral adjunct medication and DAT reduce daily OFF-time, clinically meaningful OFF periods often persist. This is where on-demand therapies provide rapid symptom relief and address the limitations of conventional oral medication and DAT. Hence, more regular, even daily use of on-demand therapies may improve quality of life in patients with PD. However, the potential impact of on-demand therapies on non-motor OFF periods needs further investigation. Side effects, handling and economic considerations should be taken into account. This expert perspective concludes that given the high prevalence and clinical relevance of fluctuations, on-demand therapies may be considered as an integral component of standard PD management rather than solely as a rescue option in rare emergency situations. Implementation may be particularly beneficial for patients experiencing early-morning-OFFs, delayed and no-ONs but also predictable and unpredictable OFFs.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149043326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early clinical experience with IPX203 in Parkinson's disease with motor fluctuations.","authors":"S Isaacson, W H Jost, J Isaacson","doi":"10.1007/s00702-026-03299-6","DOIUrl":"https://doi.org/10.1007/s00702-026-03299-6","url":null,"abstract":"<p><p>Motor fluctuations remain a major challenge in the treatment of Parkinson's disease (PD). IPX203 is a novel extended-release formulation of levodopa/carbidopa designed to provide rapid onset of benefit while maintaining therapeutic levodopa concentrations for a longer duration than immediate-release formulations. This review summarizes the formulation, pharmacokinetic profile, and clinical efficacy of IPX203 and discusses early clinical experience following its introduction into routine practice in the United States. Phase 2 studies demonstrated rapid levodopa absorption and prolonged plasma exposure, while the phase 3 RISE-PD trial showed significantly greater Good ON time with fewer daily doses compared with optimized immediate-release levodopa/carbidopa. The unique formulation combines immediate-release granules with mucoadhesive extended-release pellets that prolong levodopa delivery within the proximal small intestine. Early clinical experience suggests that many patients achieve meaningful improvements in motor fluctuations, treatment convenience, and overnight symptom control following conversion to IPX203. Three representative patient vignettes illustrate common clinical scenarios and practical approaches to treatment optimization. IPX203 provides a novel oral levodopa/carbidopa delivery strategy that combines rapid onset with prolonged duration of benefit. Clinical trial data and early clinical experience support its use as an effective option for patients with PD experiencing motor fluctuations and highlight the importance of individualized treatment optimization to maximize therapeutic benefit.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum β-catenin, GSK-3β, and IL-6 levels in medication-naive children with ADHD: a preliminary case-control study.","authors":"Esen Yıldırım Demirdöğen, Mehmet Akif Akinci, Abdullah Bozkurt, Bahadır Turan, Hatice Alarslan, Esra Laloğlu, Hilal İmamoğlu Dülgeroğlu","doi":"10.1007/s00702-026-03290-1","DOIUrl":"https://doi.org/10.1007/s00702-026-03290-1","url":null,"abstract":"<p><p>Attention-deficit/hyperactivity disorder (ADHD) has been associated with alterations in neurodevelopmental signaling pathways and inflammatory processes. This study compared serum β-catenin, glycogen synthase kinase-3 beta (GSK-3β), and interleukin-6 (IL-6) levels between medication-naive children with ADHD and healthy controls and examined associations among these biomarkers. Forty-five medication-naive children aged 7-13 years with ADHD and 45 healthy controls were included. ADHD diagnoses followed DSM-5 criteria. Serum β-catenin, GSK-3β, and IL-6 levels were measured by enzyme-linked immunosorbent assay. Group differences were assessed using covariate-adjusted analyses (age, sex, BMI percentile) with Bonferroni correction. Correlations were examined in the ADHD group, control group, and total cohort. Serum GSK-3β and IL-6 levels were higher in the ADHD group than in controls; both differences remained significant after covariate adjustment and Bonferroni correction (p<.001). β-catenin levels were lower in the ADHD group in the unadjusted analysis but were not significant after correction. Within the ADHD group, β-catenin, GSK-3β, and IL-6 showed correlations that remained significant after correction. No significant correlations were observed in the control group; in the total cohort, only the GSK-3β-IL-6 correlation remained significant after correction. No biomarker was associated with symptom severity. Medication-naive children with ADHD showed higher serum GSK-3β and IL-6 levels than controls, warranting further investigation of peripheral signaling and inflammatory differences, though the absence of technical replicates warrants caution. The β-catenin finding was not confirmed after correction. Because phosphorylated forms were not assessed, the findings do not establish altered Wnt pathway activity or GSK-3β function. Longitudinal and functional studies are needed to clarify these findings.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats.","authors":"Guilherme Lodetti, Henrique Redivo, Amanda Gomes Teixeira, Ana Caroline Salvador de Farias, Lucas de Oliveira Paccagnan, João Pedro Veronezi Rohling, Anna Thereza Endler, Elen Perego Zampronio, Daiane Depicoli de Souza, Vitória Formentin Assis, Edson de Oliveira Zaldguer, Fabiana Pereira Santos, Beatriz Aparecida Passos Bismara Paranhos, Mauricio Yonamine, Rafael Mariano de Bitencourt, Gislaine Zilli Réus, Eduardo Pacheco Rico","doi":"10.1007/s00702-026-03287-w","DOIUrl":"https://doi.org/10.1007/s00702-026-03287-w","url":null,"abstract":"<p><p>Pharmacotherapy for depression is commonly prescribed, yet fewer than half of patients achieve remission with a single treatment. Many also experience intolerable side effects, highlighting the need for new treatment approaches. Classic psychedelics interact with the serotonin (5-HT) receptor class and are therefore strongly involved in the treatment of psychiatric illnesses such as depression, anxiety, and substance abuse, demonstrating great therapeutic potential. Specifically, Ayahuasca (AYA) is primarily used for physical or spiritual healing, and the effects resulting from its use are related to its serotonergic activation. Thus, the present study aimed to evaluate the behavioral and neurochemical effects of ayahuasca treatment in Wistar rats subjected to an animal model of depression induced by maternal deprivation (MD). To induce depressive-like behavior, MD was performed on the pups for 3 h/day for 10 days (1st to 10th day of life). Subsequently, rats underwent behavioral testing to assess anxiety- and depressive-like behavior using the elevated plus maze, open field test, splash test, and forced swim test. The levels of dopamine (DA), serotonin (5-HT), brain-derived neurotrophic factor (BDNF), antioxidant enzymes superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activities, and oxidative stress biomarkers were assessed in the frontal cortex, hippocampus, and striatum 15 days after ayahuasca administration. MD promoted increased anxiety-like and depressive-like behaviors. Also, anxiety-like and depressive-like behaviors, as well as decreased BDNF and monoamine levels and increased oxidative stress induced by this model, were attenuated by treatment with a single dose of AYA, demonstrating significant therapeutic potential. The findings highlight the need for translational research of new pharmacological approaches for MDD.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}